Durability of Glucose-Lowering Effect of the First Administration of Dulaglutide: A Retrospective, Single-Center, Single-Arm Study.

Matsushita M, Chujo D, Tonoike M, Kajio H

Diabetes therapy : research, treatment and education of diabetes and related disorders28 Jul 2018Cited by 2 (Europe PMC)

PMID30056503PMCIDPMC6167306DOI10.1007/s13300-018-0474-5PepBankPUB-30056503

Read at source PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyEfficacy outcome
In patients with T2D, the first dulaglutide dose was linked to lower mean glucose through 5 days compared with pretreatment.
In plain wordsIn patients with T2D, the first dulaglutide dose was linked to lower mean glucose through 5 days compared with pretreatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseMean glucose
Study
n = 15
Comparator
Before first dulaglutide administration
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Last day with significant change after first dose
5 days
mean glucose
Source sentences
Summary
The mean glucose levels decreased significantly from 1 day before 1st Dula up to 5 days thereafter
1 context sentence(design, population, supporting numbers)
Summary · context
This study had a retrospective, single-center, and single-arm design in a clinical setting and was conducted between April 2016 and March 2017. We investigated the changes and fluctuations in glucose level in 15 patients with T2D using a continuous glucose monitor, from 1 day before the first admini…
Report a problemFND-3005650301
02HumanObservational studyEfficacy outcome
In patients with T2D, the first dulaglutide dose was linked to improved glucose standard deviation through 3 days compared with pretreatment.
In plain wordsIn patients with T2D, the first dulaglutide dose was linked to improved glucose standard deviation through 3 days compared with pretreatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseGlucose standard deviation
Study
n = 15
Comparator
Before first dulaglutide administration
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Last day with significant change after first dose
3 days
glucose standard deviation
Source sentences
Summary
whereas the standard deviation, mean amplitude of glucose excursion, and percentage of the glucose levels > 180 mg/dL were significantly improved only up to 3, 2, and 3 days after the 1st Dula, respectively, compared to those before administration.
1 context sentence(design, population, supporting numbers)
Summary · context
This study had a retrospective, single-center, and single-arm design in a clinical setting and was conducted between April 2016 and March 2017. We investigated the changes and fluctuations in glucose level in 15 patients with T2D using a continuous glucose monitor, from 1 day before the first admini…
Report a problemFND-3005650302
03HumanObservational studyEfficacy outcome
In patients with T2D, the first dulaglutide dose was linked to improved glucose excursion amplitude through 2 days compared with pretreatment.
In plain wordsIn patients with T2D, the first dulaglutide dose was linked to improved glucose excursion amplitude through 2 days compared with pretreatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseMean amplitude of glucose excursion
Study
n = 15
Comparator
Before first dulaglutide administration
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Last day with significant change after first dose
2 days
mean amplitude of glucose excursion
Source sentences
Summary
whereas the standard deviation, mean amplitude of glucose excursion, and percentage of the glucose levels > 180 mg/dL were significantly improved only up to 3, 2, and 3 days after the 1st Dula, respectively, compared to those before administration.
1 context sentence(design, population, supporting numbers)
Summary · context
This study had a retrospective, single-center, and single-arm design in a clinical setting and was conducted between April 2016 and March 2017. We investigated the changes and fluctuations in glucose level in 15 patients with T2D using a continuous glucose monitor, from 1 day before the first admini…
Report a problemFND-3005650303
04HumanObservational studyEfficacy outcome
In patients with T2D, the first dulaglutide dose was linked to improved high-glucose percentage through 3 days compared with pretreatment.
In plain wordsIn patients with T2D, the first dulaglutide dose was linked to improved high-glucose percentage through 3 days compared with pretreatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePercentage of glucose above 180 mg/dL
Study
n = 15
Comparator
Before first dulaglutide administration
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Last day with significant change after first dose
3 days
percentage of glucose above 180 mg/dL
Source sentences
Summary
whereas the standard deviation, mean amplitude of glucose excursion, and percentage of the glucose levels > 180 mg/dL were significantly improved only up to 3, 2, and 3 days after the 1st Dula, respectively, compared to those before administration.
1 context sentence(design, population, supporting numbers)
Summary · context
This study had a retrospective, single-center, and single-arm design in a clinical setting and was conducted between April 2016 and March 2017. We investigated the changes and fluctuations in glucose level in 15 patients with T2D using a continuous glucose monitor, from 1 day before the first admini…
Report a problemFND-3005650304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.